Could your own immune cells beat advanced melanoma?

NCT ID NCT06120712

Completed Disease control Sponsor: Shanghai Juncell Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. The study enrolled 18 participants and looked at safety and whether the tumors shrank.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GC101 TIL (tumor-infiltrating lymphocytes, a type of immune cell taken from the patient's own tumor)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced melanoma who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 18 participants, so results may not apply to everyone. The treatment involves serious side effects and may not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug-Related Side Effects and Adverse Reactions melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVERSE DRUG EVENT EFFICACY MELANOMA SAFETY TUMOR INFILTRATING LYMPHOCYTES

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.